Combination budesonide/formoterol inhaler as sole reliever therapy in Māori and Pacific people with mild and moderate asthma. Hardy, J., Tewhaiti-Smith, J., Baggott, C., Fingleton, J., Semprini, A., Holliday, M., Hancox, R. J., Weatherall, M., & Harwood, M. The New Zealand Medical Journal, 133(1520):61–72, August, 2020. abstract bibtex AIM: In the PRACTICAL study, as-needed budesonide/formoterol reduced the rate of severe exacerbations compared with maintenance budesonide plus as-needed terbutaline. In a pre-specified analysis we analysed the efficacy in Māori and Pacific peoples, populations with worse asthma outcomes. METHOD: The PRACTICAL study was a 52-week, open-label, parallel group, randomised controlled trial of 890 adults with mild to moderate asthma, who were randomised to budesonide/formoterol Turbuhaler 200/6mcg one actuation as required or budesonide Turbuhaler 200mcg one actuation twice daily and terbutaline Turbuhaler 250mcg two actuations as required. The primary outcome was rate of severe exacerbations. The analysis strategy was to test an ethnicity-treatment interaction term for each outcome variable. RESULTS: Seventy-two participants (8%) identified as Māori, 36 participants (4%) as Pacific ethnicity. There was no evidence that ethnicity was an effect modifier for severe exacerbations (P interaction 0.70). CONCLUSION: The reduction in severe exacerbation risk with budesonide-formoterol reliever compared with maintenance budesonide was similar in Māori and Pacific adults compared with New Zealand European/Other.
@article{hardy_combination_2020,
title = {Combination budesonide/formoterol inhaler as sole reliever therapy in {Māori} and {Pacific} people with mild and moderate asthma},
volume = {133},
issn = {1175-8716},
abstract = {AIM: In the PRACTICAL study, as-needed budesonide/formoterol reduced the rate of severe exacerbations compared with maintenance budesonide plus as-needed terbutaline. In a pre-specified analysis we analysed the efficacy in Māori and Pacific peoples, populations with worse asthma outcomes.
METHOD: The PRACTICAL study was a 52-week, open-label, parallel group, randomised controlled trial of 890 adults with mild to moderate asthma, who were randomised to budesonide/formoterol Turbuhaler 200/6mcg one actuation as required or budesonide Turbuhaler 200mcg one actuation twice daily and terbutaline Turbuhaler 250mcg two actuations as required. The primary outcome was rate of severe exacerbations. The analysis strategy was to test an ethnicity-treatment interaction term for each outcome variable.
RESULTS: Seventy-two participants (8\%) identified as Māori, 36 participants (4\%) as Pacific ethnicity. There was no evidence that ethnicity was an effect modifier for severe exacerbations (P interaction 0.70).
CONCLUSION: The reduction in severe exacerbation risk with budesonide-formoterol reliever compared with maintenance budesonide was similar in Māori and Pacific adults compared with New Zealand European/Other.},
language = {eng},
number = {1520},
journal = {The New Zealand Medical Journal},
author = {Hardy, Jo and Tewhaiti-Smith, Jordan and Baggott, Christina and Fingleton, James and Semprini, Alex and Holliday, Mark and Hancox, Robert J. and Weatherall, Mark and Harwood, Matire},
month = aug,
year = {2020},
pmid = {32994594},
keywords = {Administration, Inhalation, Adult, Anti-Asthmatic Agents, Asthma, Bronchodilator Agents, Budesonide, Budesonide, Formoterol Fumarate Drug Combination, Case-Control Studies, Disease Progression, Drug Therapy, Combination, Ethnic Groups, Female, Humans, Male, Middle Aged, Nebulizers and Vaporizers, New Zealand, Outcome Assessment, Health Care, Terbutaline, Treatment Outcome},
pages = {61--72},
}
Downloads: 0
{"_id":"Qs9hoYMFnpn2BXgDe","bibbaseid":"hardy-tewhaitismith-baggott-fingleton-semprini-holliday-hancox-weatherall-etal-combinationbudesonideformoterolinhalerassolerelievertherapyinmoriandpacificpeoplewithmildandmoderateasthma-2020","author_short":["Hardy, J.","Tewhaiti-Smith, J.","Baggott, C.","Fingleton, J.","Semprini, A.","Holliday, M.","Hancox, R. J.","Weatherall, M.","Harwood, M."],"bibdata":{"bibtype":"article","type":"article","title":"Combination budesonide/formoterol inhaler as sole reliever therapy in Māori and Pacific people with mild and moderate asthma","volume":"133","issn":"1175-8716","abstract":"AIM: In the PRACTICAL study, as-needed budesonide/formoterol reduced the rate of severe exacerbations compared with maintenance budesonide plus as-needed terbutaline. In a pre-specified analysis we analysed the efficacy in Māori and Pacific peoples, populations with worse asthma outcomes. METHOD: The PRACTICAL study was a 52-week, open-label, parallel group, randomised controlled trial of 890 adults with mild to moderate asthma, who were randomised to budesonide/formoterol Turbuhaler 200/6mcg one actuation as required or budesonide Turbuhaler 200mcg one actuation twice daily and terbutaline Turbuhaler 250mcg two actuations as required. The primary outcome was rate of severe exacerbations. The analysis strategy was to test an ethnicity-treatment interaction term for each outcome variable. RESULTS: Seventy-two participants (8%) identified as Māori, 36 participants (4%) as Pacific ethnicity. There was no evidence that ethnicity was an effect modifier for severe exacerbations (P interaction 0.70). CONCLUSION: The reduction in severe exacerbation risk with budesonide-formoterol reliever compared with maintenance budesonide was similar in Māori and Pacific adults compared with New Zealand European/Other.","language":"eng","number":"1520","journal":"The New Zealand Medical Journal","author":[{"propositions":[],"lastnames":["Hardy"],"firstnames":["Jo"],"suffixes":[]},{"propositions":[],"lastnames":["Tewhaiti-Smith"],"firstnames":["Jordan"],"suffixes":[]},{"propositions":[],"lastnames":["Baggott"],"firstnames":["Christina"],"suffixes":[]},{"propositions":[],"lastnames":["Fingleton"],"firstnames":["James"],"suffixes":[]},{"propositions":[],"lastnames":["Semprini"],"firstnames":["Alex"],"suffixes":[]},{"propositions":[],"lastnames":["Holliday"],"firstnames":["Mark"],"suffixes":[]},{"propositions":[],"lastnames":["Hancox"],"firstnames":["Robert","J."],"suffixes":[]},{"propositions":[],"lastnames":["Weatherall"],"firstnames":["Mark"],"suffixes":[]},{"propositions":[],"lastnames":["Harwood"],"firstnames":["Matire"],"suffixes":[]}],"month":"August","year":"2020","pmid":"32994594","keywords":"Administration, Inhalation, Adult, Anti-Asthmatic Agents, Asthma, Bronchodilator Agents, Budesonide, Budesonide, Formoterol Fumarate Drug Combination, Case-Control Studies, Disease Progression, Drug Therapy, Combination, Ethnic Groups, Female, Humans, Male, Middle Aged, Nebulizers and Vaporizers, New Zealand, Outcome Assessment, Health Care, Terbutaline, Treatment Outcome","pages":"61–72","bibtex":"@article{hardy_combination_2020,\n\ttitle = {Combination budesonide/formoterol inhaler as sole reliever therapy in {Māori} and {Pacific} people with mild and moderate asthma},\n\tvolume = {133},\n\tissn = {1175-8716},\n\tabstract = {AIM: In the PRACTICAL study, as-needed budesonide/formoterol reduced the rate of severe exacerbations compared with maintenance budesonide plus as-needed terbutaline. In a pre-specified analysis we analysed the efficacy in Māori and Pacific peoples, populations with worse asthma outcomes.\nMETHOD: The PRACTICAL study was a 52-week, open-label, parallel group, randomised controlled trial of 890 adults with mild to moderate asthma, who were randomised to budesonide/formoterol Turbuhaler 200/6mcg one actuation as required or budesonide Turbuhaler 200mcg one actuation twice daily and terbutaline Turbuhaler 250mcg two actuations as required. The primary outcome was rate of severe exacerbations. The analysis strategy was to test an ethnicity-treatment interaction term for each outcome variable.\nRESULTS: Seventy-two participants (8\\%) identified as Māori, 36 participants (4\\%) as Pacific ethnicity. There was no evidence that ethnicity was an effect modifier for severe exacerbations (P interaction 0.70).\nCONCLUSION: The reduction in severe exacerbation risk with budesonide-formoterol reliever compared with maintenance budesonide was similar in Māori and Pacific adults compared with New Zealand European/Other.},\n\tlanguage = {eng},\n\tnumber = {1520},\n\tjournal = {The New Zealand Medical Journal},\n\tauthor = {Hardy, Jo and Tewhaiti-Smith, Jordan and Baggott, Christina and Fingleton, James and Semprini, Alex and Holliday, Mark and Hancox, Robert J. and Weatherall, Mark and Harwood, Matire},\n\tmonth = aug,\n\tyear = {2020},\n\tpmid = {32994594},\n\tkeywords = {Administration, Inhalation, Adult, Anti-Asthmatic Agents, Asthma, Bronchodilator Agents, Budesonide, Budesonide, Formoterol Fumarate Drug Combination, Case-Control Studies, Disease Progression, Drug Therapy, Combination, Ethnic Groups, Female, Humans, Male, Middle Aged, Nebulizers and Vaporizers, New Zealand, Outcome Assessment, Health Care, Terbutaline, Treatment Outcome},\n\tpages = {61--72},\n}\n\n","author_short":["Hardy, J.","Tewhaiti-Smith, J.","Baggott, C.","Fingleton, J.","Semprini, A.","Holliday, M.","Hancox, R. J.","Weatherall, M.","Harwood, M."],"key":"hardy_combination_2020","id":"hardy_combination_2020","bibbaseid":"hardy-tewhaitismith-baggott-fingleton-semprini-holliday-hancox-weatherall-etal-combinationbudesonideformoterolinhalerassolerelievertherapyinmoriandpacificpeoplewithmildandmoderateasthma-2020","role":"author","urls":{},"keyword":["Administration","Inhalation","Adult","Anti-Asthmatic Agents","Asthma","Bronchodilator Agents","Budesonide","Budesonide","Formoterol Fumarate Drug Combination","Case-Control Studies","Disease Progression","Drug Therapy","Combination","Ethnic Groups","Female","Humans","Male","Middle Aged","Nebulizers and Vaporizers","New Zealand","Outcome Assessment","Health Care","Terbutaline","Treatment Outcome"],"metadata":{"authorlinks":{}}},"bibtype":"article","biburl":"https://api.zotero.org/users/6607533/collections/EUK4Z2Y3/items?key=hGXLq241MCQA3ow7rlTIV2gY&format=bibtex&limit=100","dataSources":["g6GzqSeiNQrL4uwxq","x3a5YBvn82E6RBLXv","EJNmxqZX8tAuYtNBY","CfMcCM7QT97iZEsTA","rhgC4BmfWie6Lm3F7"],"keywords":["administration","inhalation","adult","anti-asthmatic agents","asthma","bronchodilator agents","budesonide","budesonide","formoterol fumarate drug combination","case-control studies","disease progression","drug therapy","combination","ethnic groups","female","humans","male","middle aged","nebulizers and vaporizers","new zealand","outcome assessment","health care","terbutaline","treatment outcome"],"search_terms":["combination","budesonide","formoterol","inhaler","sole","reliever","therapy","ori","pacific","people","mild","moderate","asthma","hardy","tewhaiti-smith","baggott","fingleton","semprini","holliday","hancox","weatherall","harwood"],"title":"Combination budesonide/formoterol inhaler as sole reliever therapy in Māori and Pacific people with mild and moderate asthma","year":2020}